India's Zim Laboratories up after getting marketing authorization for migraine drug in Australia

Zim Laboratories

21/07/2025 09:58

** India's pharma products manufacturer Zim Laboratories ZIML.NS rises 2.03% to 121.28 rupees

** Co receives marketing authorization from the Therapeutic Goods Administration (TGA) of Australia for its Rizatriptan oral strips, used to treat migraines

** Development marks co's first marketing authorization in Australia

** YTD, ZIML shares up ~13.5%

(Reporting by Ananta Agarwal in Bengaluru)

((Ananta.Agarwal@thomsonreuters.com))